7.0T Magnetic Resonance Imaging Study for Hepatic Encephalopathy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jing Tang
- Phone Number: +8618001184224
- Email: jessietang301@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100853
- Chinese PLA General Hospital
-
Contact:
- Jing Tang
- Phone Number: +8618001184224
- Email: jessietang301@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with clinical suspected or diagnosed hepatic encephalopathy according to relevant guidelines.The patient's education level is above primary school level.
- Regular follow-up.
Exclusion Criteria:
- Contraindications to MRI.
- Patients with cerebrovascular disease, brain tumors, epilepsy, other neurodegenerative disease.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
7.0T Research
With the advantages of 7.0TMRI, we detect the imaging characteristics of patients with hepatic encephalopathy (HE).
|
7.0T MRI-Scan
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional connectivity and structural alterations between individuals with different subtypes of HE and healthy subjects.
Time Frame: 5 years
|
Functional connectivity calculation is mainly based on the BOLD sequence, which is used to describe the degree of connectivity between different brain regions and reflect the functional activity of the brain.
Gray matter (GM) morphological destruction, cortical thickness, and subcortical nuclear volume in patients with hepatic encephalopathy were analyzed based on structural magnetic resonance imaging(sMRI).
|
5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between spectral features of clinical variables and spectral features of imaging.
Time Frame: 5 years
|
The clinical variable spectrum characteristics were constructed using the patients' medical records and test data.
The distribution characteristics of clinical psychological characteristics and imaging spectrum characteristics were compared using a multidimensional matrix, and gene-imaging association analysis was used to evaluate imaging changes.
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Xin Lou, Chinese PLA General Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Hepatic encephalopathy-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.